» Articles » PMID: 8646552

Lack of Persistence of E1- Recombinant Adenoviral Vectors Containing a Temperature-sensitive E2A Mutation in Immunocompetent Mice and Hemophilia B Dogs

Overview
Journal Gene Ther
Date 1996 Mar 1
PMID 8646552
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Two recombinant adenoviruses expressing either human alpha 1-antitrypsin (hAAT) or canine factor IX (cFIX) were modified so that they also contained a temperature-sensitive mutation (ts125) in the DNA binding protein encoded within the viral E2A region. The effects of the inclusion of the ts125 mutation on transgene expression in vivo were evaluated in Balb/c mice and hemophilia B dogs by comparison with adenoviral vectors containing the same transgene but lacking the ts125 mutation. No significant differences in the duration of transgene expression were observed in either animal model. Insufficiency of the ts125 mutation in the prolongation of transgene expression in these two animal models suggests that further modification of the vector backbone may be required to achieve long-term gene expression in a wide variety of applications. Additionally, humoral immune response to transgene products has been demonstrated in immunocompetent animal models, which will also need to be surmounted for long-term efficacy in disease treatment by gene therapy.

Citing Articles

Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses.

Shoushtari M, Roohvand F, Salehi-Vaziri M, Arashkia A, Bakhshi H, Azadmanesh K Hum Vaccin Immunother. 2022; 18(5):2079323.

PMID: 35714271 PMC: 9481145. DOI: 10.1080/21645515.2022.2079323.


Stimulus-responsive viral vectors for controlled delivery of therapeutics.

Brun M, Gomez E, Suh J J Control Release. 2017; 267:80-89.

PMID: 28842318 PMC: 5723212. DOI: 10.1016/j.jconrel.2017.08.021.


Helper-Dependent Adenoviral Vectors.

Rosewell A, Vetrini F, Ng P J Genet Syndr Gene Ther. 2014; Suppl 5.

PMID: 24533227 PMC: 3923448. DOI: 10.4172/2157-7412.s5-001.


Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives.

Vetrini F, Ng P Viruses. 2011; 2(9):1886-1917.

PMID: 21994713 PMC: 3186006. DOI: 10.3390/v2091886.


Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Nichols T, Dillow A, Franck H, Merricks E, Raymer R, Bellinger D ILAR J. 2009; 50(2):144-67.

PMID: 19293459 PMC: 3101868. DOI: 10.1093/ilar.50.2.144.